Parkside Financial Bank & Trust’s Crinetics Pharmaceuticals CRNX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.68K	Hold	45	–	–	﹤0.01%	2246
2026 Q1	$1.64K	Sell	45 -15	-25%	-$670	﹤0.01%	2191
2025 Q4	$2.79K	Buy	60 +15	+33%	+$668	﹤0.01%	1989
2025 Q3	$1.87K	Sell	45 -2	-4%	-$64	﹤0.01%	2051
2025 Q2	$1.35K	Buy	47 +2	+4%	+$62	﹤0.01%	2139
2025 Q1	$1.51K	Buy	+45	New	+$1.68K	﹤0.01%	1968

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parkside Financial Bank & Trust's CRNX Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 45 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #2246.

Parkside Financial Bank & Trust first reported a position in CRNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.79K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Parkside Financial Bank & Trust held 45 shares of Crinetics Pharmaceuticals worth $1.68K as of Q2 2026.
Parkside Financial Bank & Trust left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
Crinetics Pharmaceuticals made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2246 holding.
Parkside Financial Bank & Trust first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Parkside Financial Bank & Trust's Crinetics Pharmaceuticals position peaked at $2.79K in Q4 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.